Cargando…
Emerging pharmaceutical therapies for COPD
COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediator...
Autores principales: | Lakshmi, Sowmya P, Reddy, Aravind T, Reddy, Raju C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/ https://www.ncbi.nlm.nih.gov/pubmed/28790817 http://dx.doi.org/10.2147/COPD.S121416 |
Ejemplares similares
-
Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
por: Reddy, Aravind T, et al.
Publicado: (2020) -
PPARγ in Bacterial Infections: A Friend or Foe?
por: Reddy, Aravind T., et al.
Publicado: (2016) -
PPARγ as a Novel Therapeutic Target in Lung Cancer
por: Reddy, Aravind T., et al.
Publicado: (2016) -
PPAR Agonists for the Prevention and Treatment of Lung Cancer
por: Lakshmi, Sowmya P., et al.
Publicado: (2017) -
The Nitrated Fatty Acid 10-Nitro-oleate Diminishes Severity of LPS-Induced Acute Lung Injury in Mice
por: Reddy, Aravind T., et al.
Publicado: (2012)